Market Overview

ArthroCare Buys ENTrigue Surgical for $45M in Cash

Related ARTC
Market Wrap For February 3: Bears In Complete and Absolute Control
Mid-Afternoon Market Update: Markets Continue to Decline on Disappointing ISM Number Among Other Factors

ArthroCare Corp. (NASDAQ: ARTC), a leader in developing state-of-the-art, minimally invasive surgical products, today announced that it has completed the acquisition of ENTrigue Surgical, Inc., a privately held Delaware corporation (“ENTrigue”), in an all cash transaction.

Pursuant to a Merger Agreement, ArthroCare paid $45 million in cash, subject to customary working capital adjustments and an amount held in escrow for indemnification. In addition, the previous shareholders of ENTrigue will have the right to receive contingent consideration on each anniversary of the closing for each of the next five years based on the increase in net sales during each twelve-month period of ENTrigue products multiplied by an agreed upon factor.

More than 30 million people in the United States are estimated to suffer from sinusitis, which is a condition characterized by an inflammation and infection of the nasal sinuses. Approximately 500,000 sinusitis patients are treated surgically in the United States each year. ENTrigue designs and develops innovative implants, disposables and instruments for endoscopic sinus surgery including balloon dilation and will now operate within ArthroCare's ENT product area as a complement to the ArthroCare Coblation® and Rapid Rhino® product lines currently being used by ENT surgeons worldwide.

Posted-In: News M&A


Related Articles (ARTC)

View Comments and Join the Discussion!

UPDATE: IHS Raises Tablet Panel Shipment Forecast for 2013 to 262M Displays

RBA Keeps Rates On Hold, Provides 'Scope For Further Easing'